TW202003548A - 特利加壓素(terlipressin)組合物及其用途 - Google Patents

特利加壓素(terlipressin)組合物及其用途 Download PDF

Info

Publication number
TW202003548A
TW202003548A TW108120774A TW108120774A TW202003548A TW 202003548 A TW202003548 A TW 202003548A TW 108120774 A TW108120774 A TW 108120774A TW 108120774 A TW108120774 A TW 108120774A TW 202003548 A TW202003548 A TW 202003548A
Authority
TW
Taiwan
Prior art keywords
terlipressin
amount
acetate
composition
pharmaceutical composition
Prior art date
Application number
TW108120774A
Other languages
English (en)
Chinese (zh)
Inventor
馬蒂爾斯 孟
Original Assignee
荷蘭商輝凌責任有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 荷蘭商輝凌責任有限公司 filed Critical 荷蘭商輝凌責任有限公司
Publication of TW202003548A publication Critical patent/TW202003548A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW108120774A 2018-06-15 2019-06-14 特利加壓素(terlipressin)組合物及其用途 TW202003548A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862685447P 2018-06-15 2018-06-15
US62/685,447 2018-06-15

Publications (1)

Publication Number Publication Date
TW202003548A true TW202003548A (zh) 2020-01-16

Family

ID=67742882

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108120774A TW202003548A (zh) 2018-06-15 2019-06-14 特利加壓素(terlipressin)組合物及其用途

Country Status (9)

Country Link
US (1) US11931398B2 (enExample)
EP (1) EP3806823A1 (enExample)
JP (2) JP7523775B2 (enExample)
CN (1) CN112969449B (enExample)
BR (1) BR112020025380A2 (enExample)
CA (1) CA3103215A1 (enExample)
MX (1) MX2020013389A (enExample)
TW (1) TW202003548A (enExample)
WO (1) WO2019239386A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020128499A1 (en) * 2018-12-21 2020-06-25 Arecor Limited Novel composition
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN114177147B (zh) * 2021-12-15 2023-05-23 福建省闽东力捷迅药业股份有限公司 一种注射用特利加压素的制备方法以及制得的注射用特利加压素
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1244794A (zh) * 1997-11-06 2000-02-16 奥尔班公司 用于药物释放的稳定的干燥药物组合物及其制备方法
NZ569836A (en) * 2006-02-10 2010-09-30 Ferring Bv Novel compounds
CN102068685A (zh) * 2010-04-09 2011-05-25 深圳翰宇药业股份有限公司 一种特利加压素制剂及其制备方法
CN102440957B (zh) * 2011-12-16 2013-09-25 深圳市健元医药科技有限公司 醋酸特利加压素鼻腔喷雾剂及其制备方法
AU2013211873B2 (en) 2012-01-26 2018-04-26 Endoshape, Inc. Systems, devices, and methods for delivering a lumen occlusion device using distal and/or proximal control
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AU2014256944B2 (en) * 2013-04-26 2019-06-27 La Jolla Pharma, Llc Compositions and methods for treating renal failure
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN106188218B (zh) * 2016-07-14 2018-11-23 江苏诺泰澳赛诺生物制药股份有限公司 一种提高多肽原料药稳定性的方法
GB201721846D0 (en) 2017-12-22 2018-02-07 Arecor Ltd Novel composition
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형

Also Published As

Publication number Publication date
CN112969449A (zh) 2021-06-15
CA3103215A1 (en) 2019-12-19
CN112969449B (zh) 2025-03-11
WO2019239386A1 (en) 2019-12-19
JP2021527084A (ja) 2021-10-11
BR112020025380A2 (pt) 2021-05-18
US11931398B2 (en) 2024-03-19
JP7523775B2 (ja) 2024-07-29
EP3806823A1 (en) 2021-04-21
JP2024086898A (ja) 2024-06-28
MX2020013389A (es) 2021-03-31
US20210161995A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
US11872266B2 (en) Rapid-acting insulin compositions
JP2024086898A (ja) テルリプレシン組成物及びその使用
EP3536380B1 (en) Rapid-acting insulin compositions
EP3532029B1 (en) Liquid pharmaceutical composition
EP2525796B1 (en) Aqueous solution comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
JP2013535422A5 (enExample)
CN103070871B (zh) 一种氟维司群的药物组合物
TWI468161B (zh) 組合藥劑之醫藥產品、試劑及用途
JP2019502751A5 (enExample)
EP4732829A1 (en) Glp-1-fc-fgf21 double-target fusion protein composition, and injection and use thereof
JP6856813B1 (ja) 亜鉛点滴静注用製剤
CN107257683A (zh) C1酯酶抑制剂的药物制剂
JP7618235B2 (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法
WO2024027549A1 (zh) 一种含有吡咯类胃酸分泌抑制剂的药物组合物及其制备方法
US11324752B2 (en) Imeglimin for preventing and/or treating hepatocellular carcinoma
KR20210126515A (ko) 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
US20250049802A1 (en) Combination therapies and uses for treating cancer
CN103830217B (zh) 丙酮酸钠在制备缓解高氯性酸中毒药物中的应用
WO2025190304A1 (zh) 包含glp-1和gip双受体激动剂的药物组合物及其用途
TW201440782A (zh) 米卡芬淨或其鹽的醫藥組成物
CN117257936A (zh) 一种阿达木单抗组合物
WO2026037397A1 (zh) Glp-1类似物的医药用途
HK1263347B (zh) 英夫利西单抗冻干制剂
HK1228824B (en) Rapid-acting insulin compositions
HK1228824A1 (en) Rapid-acting insulin compositions